Longmont offers immediate and significant future capacity to expand AGC Biologics’ end-to-end cell and gene therapy practice. The facility gives the company a centralized hub in North America that extends its global cell and gene therapy capabilities and helps ensure the security of supply for current and future customers. Through this facility, AGC Biologics expanded its process development and GMP capacity to meet early phase, late phase and commercial customer needs, ensuring security of supply for current and future customers.
Longmont has 622,000 square feet of operations and office space within six buildings on a sprawling 229-acre campus. The property also includes large amounts of undeveloped land that can be built out to add more capacity and capabilities in order to meet future needs of our customers.
The size of the campus allows AGC Biologics the flexibility to maximize the capabilities of each building to support key aspects of the cell therapy, gene therapy and viral vector process development as well as cGMP manufacturing, testing and supply chain management. The Longmont facility includes customized labs and workspaces that support manufacturing, process development, analytical development and quality control, as well as a warehouse to securely house and manage large volumes of different types of materials that support a working cell bank and a master cell bank, intermediates and final product.
The facility also comes equipped with multiple utility redundancies that safeguard the warehouse, labs, development and GMP manufacturing facilities from large-scale outages and disruptions, ensuring products are secure and protected.
GMP manufacturing suite for cell therapy practice in one centralized location where all processes are managed
Cell therapy capabilities in development laboratory and GMP manufacturing areas
Adherent and suspension-based viral vector GMP manufacturing.